INVO BioScience GAAP EPS of -$2.24 beats by $18.56, revenue of $2.22M misses by $0.49M
INVO BioScience reported Q3 GAAP EPS of -$2.24, beating estimates by $18.56, while revenue of $2.22M missed by $0.49M. Revenue grew 26.9% year-over-year. Adjusted EBITDA was -$1.0M, and cash was $3.7M at Q3's end, according to the company.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term valuation and financing risk based on the revenue miss and the reported cash balance, even with a GAAP EPS beat.
Market read
A fresh quarterly print with explicit EPS and revenue variances plus cash provides a direct catalyst for trading the stock around the earnings window.
What to watch
Cash of $3.7M (about $3.10 per share) may be the dominant risk factor for positioning, potentially outweighing the EPS beat if burn rate concerns persist.
Background
The piece summarizes INVO BioScience’s Q3 results from a press release, focusing on GAAP EPS, revenue, adjusted EBITDA, and cash at quarter-end.
Market effects
Reinforces ongoing investor focus on revenue trajectory versus accounting-driven EPS swings in small-cap fertility/biotech names.
No clear regional spillover indicated beyond US small-cap biotech sentiment.
Limited, as the disclosure is company-specific and not tied to a global macro or regulatory event.
Counterpoint
The large GAAP EPS beat could reflect non-cash items or one-time effects; if investors believe underlying operating progress is improving, the revenue miss may be viewed as temporary.
Key entities
- companyINVO BioScience, Inc.
Reported Q3 GAAP EPS, revenue, adjusted EBITDA, and cash balance in the article.


